Drug Similarities Provide Evidence Latitude, Temple Says; Diovan Example?

Pharmacologic similarity between compounds gives FDA greater latitude in the amount and type of data required for approval, Office of Medical Policy Director Robert Temple indicated during an Aug. 3 interview with "The Pink Sheet.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet